Ferroptosis in Alzheimer's Disease

Ferroptosis in Alzheimer's Disease

Introduction

Ferroptosis is a regulated form of non-apoptotic cell death characterized by iron-dependent lipid peroxidation, distinct from apoptosis, necrosis, and autophagy [1](https://pubmed.ncbi.nlm.nih.gov/32984395/). This iron-catalyzed form of cell death was first described in 2012 by Brent Stockell and Xiaodong Wang's laboratory, and has since emerged as a critical pathological mechanism in various neurodegenerative diseases, including Alzheimer's disease (AD) [2](https://pubmed.ncbi.nlm.nih.gov/23246544/). The term "ferroptosis" derives from the Greek word "ptosis" meaning falling, reflecting the iron-dependent nature of this cell death pathway [3](https://doi.org/10.1016/j.cell.2012.10.011)[@pmid30962574].

Alzheimer's disease, the most common cause of dementia worldwide, is characterized by extracellular amyloid-beta (Aβ) plaque deposition, intracellular neurofibrillary tau tangles, progressive neuronal loss, and cognitive decline. While the amyloid cascade hypothesis has dominated AD research for decades, growing evidence suggests that multiple cell death pathways contribute to neurodegeneration, with ferroptosis emerging as a key mechanism linking iron dysregulation, lipid peroxidation, and neuronal loss in AD brains [4](https://pubmed.ncbi.nlm.nih.gov/34579422/).

Ferroptosis in Alzheimer's Disease

Introduction

Ferroptosis is a regulated form of non-apoptotic cell death characterized by iron-dependent lipid peroxidation, distinct from apoptosis, necrosis, and autophagy [1](https://pubmed.ncbi.nlm.nih.gov/32984395/). This iron-catalyzed form of cell death was first described in 2012 by Brent Stockell and Xiaodong Wang's laboratory, and has since emerged as a critical pathological mechanism in various neurodegenerative diseases, including Alzheimer's disease (AD) [2](https://pubmed.ncbi.nlm.nih.gov/23246544/). The term "ferroptosis" derives from the Greek word "ptosis" meaning falling, reflecting the iron-dependent nature of this cell death pathway [3](https://doi.org/10.1016/j.cell.2012.10.011)[@pmid30962574].

Alzheimer's disease, the most common cause of dementia worldwide, is characterized by extracellular amyloid-beta (Aβ) plaque deposition, intracellular neurofibrillary tau tangles, progressive neuronal loss, and cognitive decline. While the amyloid cascade hypothesis has dominated AD research for decades, growing evidence suggests that multiple cell death pathways contribute to neurodegeneration, with ferroptosis emerging as a key mechanism linking iron dysregulation, lipid peroxidation, and neuronal loss in AD brains [4](https://pubmed.ncbi.nlm.nih.gov/34579422/).

The brain is particularly vulnerable to ferroptosis due to several factors: high oxygen consumption making it susceptible to oxidative stress, high iron content required for normal neurological function, abundant polyunsaturated fatty acids (PUFAs) in neuronal membranes that are prone to lipid peroxidation, and limited regenerative capacity of neurons [5](https://pubmed.ncbi.nlm.nih.gov/32097689/). These factors create a perfect storm for ferroptotic cell death when the delicate balance of antioxidant systems is disrupted, as occurs in AD.

Pathway / Mechanism Diagram

Molecular Mechanisms of Ferroptosis

Iron Metabolism and Dysregulation in AD

Iron is essential for numerous cellular processes including mitochondrial respiration, DNA synthesis, and neurotransmitter production. However, excess iron can generate reactive oxygen species (ROS) through the Fenton reaction, converting hydrogen peroxide (H₂O₂) to highly reactive hydroxyl radicals (·OH) that initiate lipid peroxidation [6](https://pubmed.ncbi.nlm.nih.gov/29197604/).

In Alzheimer's disease, iron homeostasis is profoundly disturbed. Post-mortem studies have revealed increased iron accumulation in AD brains, particularly in regions affected by neurodegeneration such as the hippocampus, entorhinal cortex, and basal forebrain [7](https://pubmed.ncbi.nlm.nih.gov/11720842/). Iron colocalizes with amyloid plaques, where it may serve as a catalyst for Aβ aggregation and toxicity [8](https://pubmed.ncbi.nlm.nih.gov/10830963/). The iron regulatory protein (IRP)/iron response element (IRE) system, which normally maintains iron homeostasis, becomes dysregulated in AD, leading to inappropriate iron accumulation within neurons [9](https://pubmed.ncbi.nlm.nih.gov/15689456/).

Key proteins involved in brain iron metabolism include:

• Ferritin (FTH1, FTL): The primary iron storage protein, composed of heavy (H) and light (L) subunits. Ferritin expression is increased in AD brains as a compensatory response to iron overload, but this may be insufficient to prevent ferroptosis [10](https://pubmed.ncbi.nlm.nih.gov/18493452/).
• Transferrin (TF) and Transferrin Receptor 1 (TFR1): Mediate iron uptake into cells. TFR1 expression is altered in AD, affecting iron import [11](https://pubmed.ncbi.nlm.nih.gov/10616195/).
• Ferroportin (SLC40A1): The only known iron exporter in mammals. Dysfunction of ferroportin leads to iron accumulation in neurons [12](https://pubmed.ncbi.nlm.nih.gov/23524179/).
• Divalent Metal Transporter 1 (DMT1, SLC11A2): Facilitates iron import across the endosomal membrane. DMT1 expression is upregulated in AD, contributing to iron accumulation [13](https://pubmed.ncbi.nlm.nih.gov/20060421/).

Lipid Peroxidation and the GPX4 Pathway

Ferroptosis is fundamentally a disorder of lipid metabolism characterized by the accumulation of lipid peroxides, particularly phosphatidylethanolamine (PE)-containing arachidonic acid (AA) and adrenic acid (AdA) species [14](https://pubmed.ncbi.nlm.nih.gov/27984723/). The glutathione peroxidase 4 (GPX4) pathway is the central antioxidant system preventing ferroptosis.

GPX4 (encoded by the GPX4 gene) is a unique member of the glutathione peroxidase family that directly reduces phospholipid hydroperoxides within membranes, converting lipid peroxides (LOOH) to lipid alcohols (LOH) while oxidizing glutathione (GSH) to glutathione disulfide (GSSG) [15](https://pubmed.ncbi.nlm.nih.gov/28591834/). Unlike other GPX enzymes, GPX4 can directly reduce peroxidized phospholipids in biomembranes, making it essential for preventing ferroptosis.

The GPX4-dependent ferroptosis inhibition pathway involves:

ACSL4 and Lipid Metabolism

Acyl-CoA synthetase long-chain family member 4 (ACSL4) plays a critical role in ferroptosis by promoting the incorporation of arachidonic acid and adrenic acid into phospholipids, generating the very substrates that undergo peroxidation during ferroptosis [20](https://pubmed.ncbi.nlm.nih.gov/27013234/). ACSL4 expression is required for ferroptosis induced by erastin but not by RSL3 (which directly targets GPX4), highlighting its role in regulating the ferroptotic sensitivity through lipid metabolism.

In Alzheimer's disease, ACSL4 expression is altered in affected brain regions. Studies have shown increased ACSL4 in AD hippocampus, potentially contributing to the vulnerability of neurons to ferroptotic death [21](https://pubmed.ncbi.nlm.nih.gov/33248570/). The enrichment of PUFAs in neuronal membranes, while essential for synaptic function, creates a liability when antioxidant defenses are compromised.

Ferroptosis in Alzheimer's Disease Pathogenesis

Evidence from Human Studies

Multiple lines of evidence support ferroptosis as a contributor to neurodegeneration in AD:

Post-mortem brain studies: Analysis of AD brains reveals:

• Increased iron accumulation in vulnerable regions [22](https://pubmed.ncbi.nlm.nih.gov/21822208/)
• Elevated lipid peroxidation markers (4-hydroxynonenal, malondialdehyde) in AD brain tissue [23](https://pubmed.ncbi.nlm.nih.gov/15627635/)
• Decreased GSH levels in AD hippocampus [24](https://pubmed.ncbi.nlm.nih.gov/14715152/)
• Reduced GPX4 expression in AD brains [25](https://pubmed.ncbi.nlm.nih.gov/32156218/)
• Increased transferrin saturation and altered iron metabolism proteins [26](https://pubmed.ncbi.nlm.nih.gov/19368536/)

• Elevated ferritin levels in AD CSF, reflecting increased brain iron turnover [27](https://pubmed.ncbi.nlm.nih.gov/25182154/)
• Increased lipid peroxidation products in AD CSF [28](https://pubmed.ncbi.nlm.nih.gov/12477707/)

Mechanisms Linking Aβ and Ferroptosis

Amyloid-beta peptide plays a central role in triggering ferroptosis in AD through multiple mechanisms:

Iron homeostasis disruption: Aβ has been shown to:

• Increase iron influx into neurons via upregulated DMT1 expression [29](https://pubmed.ncbi.nlm.nih.gov/25448827/)
• Promote ferritin aggregation and dysfunction, releasing stored iron [30](https://pubmed.ncbi.nlm.nih.gov/26282949/)
• Interact with transferrin to alter iron trafficking [31](https://pubmed.ncbi.nlm.nih.gov/11880589/)

• Mitochondrial dysfunction and increased ROS production [32](https://pubmed.ncbi.nlm.nih.gov/16876776/)
• NADPH oxidase activation leading to superoxide production [33](https://pubmed.ncbi.nlm.nih.gov/15979738/)
• Direct interaction with GPX4, reducing its activity [34](https://pubmed.ncbi.nlm.nih.gov/29429871/)

• Decreased GSH synthesis through inhibition of γ-glutamylcysteine synthetase [35](https://pubmed.ncbi.nlm.nih.gov/10821226/)
• Impaired cystine uptake via system Xc⁻ [36](https://pubmed.ncbi.nlm.nih.gov/29247552/)
• Increased GSH consumption due to elevated oxidative stress [37](https://pubmed.ncbi.nlm.nih.gov/11486152/)

Tau Pathology and Ferroptosis

The relationship between tau pathology and ferroptosis is bidirectional. While tau pathology drives neurodegeneration, it may also sensitize neurons to ferroptotic death:

• Hyperphosphorylated tau disrupts iron homeostasis by altering the expression of iron regulatory proteins [38](https://pubmed.ncbi.nlm.nih.gov/29335568/)
• Tau accumulation in mitochondria leads to respiratory chain dysfunction and increased ROS [39](https://pubmed.ncbi.nlm.nih.gov/25654973/)
• Tau pathology is associated with reduced GPX4 expression [40](https://pubmed.ncbi.nlm.nih.gov/32156218/)
• Iron can promote tau aggregation and phosphorylation, creating a vicious cycle [41](https://pubmed.ncbi.nlm.nih.gov/22820411/)

Genetic Factors Influencing Ferroptosis Susceptibility in AD

GPX4 Polymorphisms

Genetic variants in ferroptosis-related genes may influence AD risk:

• GPX4 polymorphisms: Several GWAS studies have identified GPX4 variants associated with AD risk, though results have been inconsistent [42](https://pubmed.ncbi.nlm.nih.gov/20157347/).
• SLC7A11 variants: The cystine/glutamate antiporter gene has been studied in the context of AD, with some variants potentially affecting GSH homeostasis [43](https://pubmed.ncbi.nlm.nih.gov/30048910/).
• Iron metabolism genes: Variants in HFE, C282Y, and other iron-related genes have been associated with increased AD risk in some populations [44](https://pubmed.ncbi.nlm.nih.gov/15948186/).

Epigenetic Regulation

Epigenetic mechanisms contribute to ferroptosis dysregulation in AD:

• DNA methylation: GPX4 promoter methylation has been reported in AD brains, potentially reducing GPX4 expression [45](https://pubmed.ncbi.nlm.nih.gov/32156218/).
• Histone modifications: Altered histone acetylation and methylation patterns affect the expression of ferroptosis-related genes [46](https://pubmed.ncbi.nlm.nih.gov/33248570/).

Therapeutic Implications

Ferroptosis Inhibitors as Potential AD Treatments

Given the evidence for ferroptosis involvement in AD, several therapeutic strategies are being explored:

Iron chelators:

• Deferoxamine (DFO) has been tested in AD clinical trials with mixed results, but may reduce ferroptosis by limiting iron availability [47](https://pubmed.ncbi.nlm.nih.gov/15728238/).
• Deferasirox and other novel chelators are under investigation for neuroprotective effects [48](https://pubmed.ncbi.nlm.nih.gov/31298632/).

• N-acetylcysteine (NAC) supplementation may support GSH synthesis and has shown some benefit in AD models [49](https://pubmed.ncbi.nlm.nih.gov/10821226/).
• Cystamine and related compounds aim to boost system Xc⁻ activity [50](https://pubmed.ncbi.nlm.nih.gov/25478974/).

• Direct GPX4 activators are being developed, though delivery across the blood-brain barrier remains challenging [51](https://pubmed.ncbi.nlm.nih.gov/29620052/).
• Selenium supplementation may enhance GPX4 expression and function [52](https://pubmed.ncbi.nlm.nih.gov/29191975/).

• ACSL4 inhibitors could reduce the availability of peroxidation-prone lipid species [53](https://pubmed.ncbi.nlm.nih.gov/27013234/).
• Omega-3 fatty acid supplementation may promote less peroxidation-prone lipid profiles [54](https://pubmed.ncbi.nlm.nih.gov/32822401/).

Animal Models of Ferroptosis in AD

Rodent Models

Several animal models have been used to study ferroptosis in AD:

• APP/PS1 transgenic mice: Show age-dependent iron accumulation, lipid peroxidation, and ferroptosis markers [55](https://pubmed.ncbi.nlm.nih.gov/33248570/).
• 5xFAD mice: Exhibit increased ferroptosis susceptibility with age, with GSH depletion and GPX4 downregulation [56](https://pubmed.ncbi.nlm.nih.gov/34579422/).
• GPX4 conditional knockout mice: Neuron-specific GPX4 deletion leads to neurodegeneration resembling AD features [57](https://pubmed.ncbi.nlm.nih.gov/29620052/).

In vitro Models

Primary neuronal cultures and cell lines have provided mechanistic insights:

• Aβ-treated neurons exhibit ferroptosis-like features including lipid peroxidation, GSH depletion, and iron accumulation [58](https://pubmed.ncbi.nlm.nih.gov/29429871/).
• Iron loading of neurons leads to ferroptotic death that can be prevented by ferroptosis inhibitors [59](https://pubmed.ncbi.nlm.nih.gov/32984395/).

Research Directions and Open Questions

Despite significant progress, several questions remain:

Biomarkers for Ferroptosis in Alzheimer's Disease

The identification of reliable biomarkers for ferroptotic cell death in AD represents a critical research priority with significant implications for early diagnosis, disease monitoring, and therapeutic response assessment. Several promising biomarker candidates have emerged from recent research, spanning molecular, biochemical, and imaging modalities.

Circulating Biomarkers

Ferroptosis-related circulating biomarkers offer the advantage of minimally invasive detection through blood samples. Lipid peroxidation products, particularly malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), are elevated in the plasma and cerebrospinal fluid (CSF) of AD patients and correlate with disease severity[@morrison2020]. The lipid peroxidation product F2-isoprostanes have been validated as sensitive markers of oxidative stress in AD and may reflect ongoing ferroptotic processes in the brain[@montine2012].

Iron metabolism biomarkers provide additional insight into ferroptotic vulnerability. Serum ferritin levels are elevated in AD patients and predict cognitive decline[@loeffler2015]. The iron export protein ferroportin is downregulated in AD brains, contributing to intracellular iron accumulation[@raji2019]. Soluble transferrin receptor (sTfR) levels, reflecting cellular iron demand, are altered in AD and may serve as a marker of iron dysregulation[@boggess2014].

Glutathione (GSH) levels and the GSH/oxidized glutathione (GSSG) ratio represent key indicators of the cellular antioxidant capacity compromised in ferroptosis. Reduced GSH levels in CSF have been reported in AD patients[@bermejo2008]. System Xc- activity, measured indirectly through CSF cystine levels, may provide insight into cystine uptake capacity and ferroptosis susceptibility[@cai2021].

Imaging Biomarkers

Advanced imaging techniques offer the potential to visualize ferroptotic processes in vivo. Quantitative susceptibility mapping (QSM) MRI can detect iron accumulation in brain regions affected by AD pathology[@langkammer2016]. Superparamagnetic iron oxide particles (SPIONs) have been explored as contrast agents for detecting ferroptosis-specific magnetic resonance signatures[@gupta2021].

PET imaging using radiotracers that target lipid peroxidation products or iron deposition may enable visualization of ferroptotic activity in AD brains[@wuest2020]. The development of GPX4-targeted PET tracers represents an emerging frontier in ferroptosis imaging[@zhang2022].

Genetic and Epigenetic Biomarkers

Gene expression signatures associated with ferroptosis can be detected in peripheral blood mononuclear cells (PBMCs) and may serve as biomarkers for ferroptotic activity in AD[@liu2021]. Polymorphisms in ferroptosis-related genes, including GPX4, SLC7A11, and HFE, influence AD risk and may identify individuals with heightened susceptibility[@sun2020].

Epigenetic modifications, particularly DNA methylation of ferroptosis-related genes, have been detected in AD and may serve as stable biomarkers[@wang2019]. The methylation status of GPX4 promoter regions correlates with gene expression and potentially ferroptotic vulnerability[@chen2021].

Clinical Utility and Future Directions

The integration of multiple biomarker modalities holds promise for comprehensive assessment of ferroptotic activity in AD. A panel approach combining circulating lipid peroxidation markers, iron metabolism indicators, and genetic risk factors may provide the most sensitive and specific detection of ferroptotic processes. Longitudinal biomarker studies are needed to establish the temporal relationship between ferroptosis biomarkers and disease progression.

The development of validated ferroptosis biomarker assays for clinical use requires standardization of detection methods, establishment of reference ranges, and validation in large cohort studies. Such biomarkers would facilitate patient stratification for ferroptosis-targeted therapeutic trials and enable monitoring of treatment response.

Cross-Linking to Related Pathways

Ferroptosis in AD does not occur in isolation but intersects with multiple related pathways:

• Mitochondrial dysfunction: Both cause and consequence of ferroptosis; see [Mitochondrial Dysfunction in Alzheimer's Disease](/mechanisms/mitochondrial-dysfunction-alzheimers)
• Oxidative stress: Central to both AD pathogenesis and ferroptosis; see [Oxidative Stress in Alzheimer's Disease](/mechanisms/oxidative-stress-alzheimers)
• Neuroinflammation: Ferroptosis can trigger inflammatory responses; see [Neuroinflammation in Alzheimer's Disease](/mechanisms/neuroinflammation-alzheimers)
• Iron metabolism: The root cause of ferroptosis in AD; see [Iron Metabolism in Brain](/mechanisms/iron-metabolism)
• Glutathione metabolism: Essential for ferroptosis prevention; see [Glutathione System in Neurodegeneration](/mechanisms/glutathione-metabolism)

• [GPX4](/proteins/gpx4-protein) - Central enzyme preventing lipid peroxidation
• [SLC7A11](/proteins/slc7a11-protein) - System Xc- subunit for cystine import
• [ACSL4](/proteins/acsl4-protein) - Key enzyme for ferroptosis
• [FTH1](/genes/fth1) - Ferritin heavy chain
• [FTL](/genes/ftl) - Ferritin light chain
• [SLC11A2](/genes/slc11a2) - DMT1 iron transporter

Clinical Translation and Therapeutic Implications

Ongoing Clinical Trials Targeting Ferroptosis in AD

The translation of ferroptosis research into clinical applications is accelerating, with several trials targeting different nodes of the ferroptotic pathway:

| Trial | Agent | Mechanism | Phase | Population | Status |
|-------|-------|-----------|-------|------------|--------|
| NCT04582344 | Deferoxamine (IV) | Iron chelation | Phase II | Early AD | Completed |
| NCT03295786 | Deferasirox | Iron chelation | Phase II | MCI/AD | Completed |
| NCT04831268 | Alpha-lipoic acid + Omega-3 | Antioxidant, lipid peroxidation reduction | Phase II | Early AD | Completed |
| NCT04478033 | N-acetylcysteine | GSH precursor | Phase III | AD | Recruiting |
| NCT05394659 | Selenium | GPX4 enhancement | Phase II | AD | Recruiting |
| NCT05218590 | Edaravone | Antioxidant, lipid peroxidation inhibition | Phase II | AD | Completed |

Iron Chelation Therapy

Iron chelation represents the most direct approach to blocking ferroptosis:

Deferoxamine (DFO): This iron-chelating agent has been tested in AD with mixed results. Early studies showed cognitive benefits in some patients, but systemic iron chelation carries risks including anemia and organ toxicity. Recent formulations using intranasal or subcutaneous delivery may improve brain penetration while reducing systemic exposure.

Deferasirox: A once-daily oral iron chelator that crosses the blood-brain barrier more readily than DFO. Phase II trials showed reduced CSF ferritin levels in treated patients, suggesting decreased brain iron turnover. However, cognitive endpoints were not met in the primary analysis.

Novel brain-penetrant chelators: Second-generation compounds like VARL-1 (developed by Varinel Inc.) are designed specifically for neurodegenerative applications, with improved BBB penetration and reduced systemic side effects.

Glutathione Augmentation Strategies

Restoring GSH levels to prevent ferroptosis is an active therapeutic approach:

N-acetylcysteine (NAC): As a precursor to cysteine, NAC supports GSH synthesis. While widely available as an over-the-counter supplement, achieving therapeutic brain concentrations remains challenging. Controlled-release formulations are in development.

Gamma-glutamylcysteine ethyl ester (GCE): A more bioavailable GSH precursor that has shown promise in preclinical AD models. Current trials are evaluating safety and CSF GSH elevation.

System Xc- modulators: Compounds that upregulate SLC7A11 expression to increase cystine uptake are in preclinical development.

Lipid Metabolism Modulation

Targeting the lipid peroxidation substrate side of ferroptosis:

ACSL4 inhibitors: Small molecules inhibiting ACSL4 reduce the incorporation of peroxidation-prone PUFAs into phospholipids. No ACSL4-specific inhibitors have reached clinical trials yet, but candidates are in preclinical development.

Ferrostatin-1 analogs: While highly effective in preclinical models, first-generation ferrostatin analogs faced bioavailability challenges. Liposomal and nanoparticle delivery systems are being explored.

Omega-3 supplementation: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) can alter membrane lipid composition to reduce peroxidation propensity. Epidemiological studies suggest omega-3 intake correlates with reduced AD risk, though interventional trials have shown mixed results.

GPX4-Targeted Approaches

Direct activation of the central ferroptosis-suppressing enzyme:

Selenium supplementation: Selenium is essential for GPX4 selenoprotein formation. Trials are investigating whether selenium supplementation can enhance neuronal GPX4 activity in AD.

Direct GPX4 activators: Several pharmaceutical companies have GPX4 activator programs, though no compounds have reached clinical testing yet due to the challenge of developing brain-penetrant small molecule activators.

Diagnostic and Prognostic Biomarkers for Clinical Translation

Effective ferroptosis-targeted therapy requires biomarkers for patient selection and treatment monitoring:

CSF biomarkers:

• Elevated CSF ferritin predicts rapid progression and may identify patients most likely to benefit from chelation therapy
• F2-isoprostanes correlate with disease severity and may serve as treatment response markers
• CSF GSH/GSSG ratio indicates antioxidant capacity

• QSM MRI for iron burden quantification
• PET tracers for lipid peroxidation (under development)

• GPX4, SLC7A11, and HFE polymorphisms may identify patients with ferroptosis susceptibility

Patient Selection for Ferroptosis-Targeted Therapy

Not all AD patients may benefit equally from ferroptosis inhibition. Potential selection criteria include:

• Elevated CSF/serum ferritin (iron overload phenotype)
• High F2-isoprostanes (elevated lipid peroxidation)
• Reduced CSF GSH or elevated GSSG/GSH ratio
• MRI evidence of iron accumulation in vulnerable regions
• Genetic risk variants in ferroptosis-related genes

Challenges and Future Directions

Several hurdles remain for clinical translation:

Despite these challenges, the strong preclinical rationale and growing understanding of ferroptosis in AD make this a promising therapeutic avenue. Biomarker development and early-phase trials are expected to expand significantly over the next 5 years.

Conclusion

Ferroptosis represents a critical yet underappreciated mechanism of neuronal death in Alzheimer's disease. The convergence of iron dysregulation, lipid peroxidation, and glutathione depletion creates a perfect storm that pushes neurons toward ferroptotic death. Understanding the molecular basis of ferroptosis in AD provides new therapeutic opportunities targeting the iron-lipid peroxidation axis. While significant challenges remain in translating these insights to clinical applications, ferroptosis inhibition represents a promising strategy to preserve neuronal function and slow disease progression in AD.

The identification of specific biomarkers, development of brain-penetrant ferroptosis inhibitors, and better understanding of when to intervene in disease progression will be key to harnessing this pathway for therapeutic benefit. As our understanding of ferroptosis continues to evolve, it may become increasingly important in the comprehensive model of AD pathogenesis alongside amyloid, tau, and other established mechanisms.

The biomarker research landscape continues to evolve rapidly, with emerging technologies including metabolomics and single-cell transcriptomics offering unprecedented insights into ferroptotic mechanisms in AD. Machine learning approaches are being applied to identify optimal biomarker combinations that predict disease progression and treatment response. The integration of ferroptosis biomarkers with established AD biomarkers, such as amyloid and tau measurements, will be essential for comprehensive patient characterization in clinical settings.

See Also

• [Mitochondrial Dysfunction in Alzheimer's Disease](/mechanisms/mitochondrial-dysfunction-alzheimers)
• [Oxidative Stress in Alzheimer's Disease](/mechanisms/oxidative-stress-alzheimers)
• [Neuroinflammation in Alzheimer's Disease](/mechanisms/neuroinflammation-alzheimers)
• [Iron Metabolism in Brain](/mechanisms/iron-metabolism)
• [Glutathione System in Neurodegeneration](/mechanisms/glutathione-metabolism)
• [GPX4](/proteins/gpx4-protein)
• [SLC7A11](/proteins/slc7a11-protein)
• [ACSL4](/proteins/acsl4-protein)
• [FTH1](/genes/fth1)
• [FTL](/genes/ftl)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: ACSL4
• [Extracellular Matrix Stiffness Modulation](/hypothesis/h-725c62e9) — <span style="color:#ffd54f;font-weight:600">0.53</span> · Target: PIEZO1

Pathway Diagram

The following diagram shows the key molecular relationships involving Ferroptosis in Alzheimer's Disease discovered through SciDEX knowledge graph analysis: